Market Tracker

01/17 3:25am ET

Mylan NV (NASDAQ:MYL)

46.64
Delayed Data
As of Jan 16
 -0.26 / -0.55%
Today’s Change
29.39
Today|||52-Week Range
47.25
+10.23%
Year-to-Date
Teva's Trisenox Gets FDA Approval as First-Line Treatment
Jan 16 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: Allergan Announces Job Cuts, Pfizer Inks Deals
Jan 05 / Zacks.com - Paid Partner Content
Allergan's (AGN) Sales Guidance for 2018 Lower Than Expected
Jan 09 / Zacks.com - Paid Partner Content
Allergan to Cut Jobs Amid Loss of Exclusivity for Key Drugs
Jan 04 / Zacks.com - Paid Partner Content
Momenta Reports Positive Top-Line Data on Antibody M281
Jan 09 / Zacks.com - Paid Partner Content
Momenta & Mylan to Initiate Trial on Biosimilar of Eylea
Jan 04 / Zacks.com - Paid Partner Content
Key Biosimilar Approvals in 2017: Progress Report
Jan 05 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close46.90
Today’s open46.70
Day’s range46.60 - 47.25
Volume5,412,728
Average volume (3 months)6,324,893
Market cap$25.2B
Data as of 4:00pm ET, 01/16/2018

Growth & Valuation

Earnings growth (last year)-45.88%
Earnings growth (this year)-7.14%
Earnings growth (next 5 years)+3.86%
Revenue growth (last year)+17.44%
P/E ratio28.4
Price/Sales1.79
Price/Book2.26

Competitors

 Today’s
change
Today’s
% change
BMRNBiomarin Pharmaceuti...+0.02+0.02%
PRGOPerrigo Company PLC-0.94-1.02%
JAZZJazz Pharmaceuticals...-0.39-0.26%
ALNYAlnylam Pharmaceutic...-4.43-3.43%
Data as of 4:02pm ET, 01/16/2018

Financials

Next reporting dateFebruary 28, 2018
EPS forecast (this quarter)$1.41
Annual revenue (last year)$11.1B
Annual profit (last year)$480.0M
Net profit margin4.32%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Generic
Chief Executive Officer &
Director
Heather M. Bresch
President &
Director
Rajiv Malik
Corporate headquarters
Hatfield, Hertfordshire

Forecasts